Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28061817 | 0.98 | NAAA (0.50) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL9358040 | 0.85 | TSHR (0.52) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL37366 | 0.83 | NAAA (0.62) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL1838958 | 0.81 | NAAA (0.67) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL1837444 | 0.81 | NAAA (0.67) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL1834574 | 0.81 | NAAA (0.67) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL1839030 | 0.81 | NAAA (0.67) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL1835519 | 0.81 | NAAA (0.67) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL1835881 | 0.81 | NAAA (0.67) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL119774 | 0.81 | NAAA (0.67) | NAAARAD52NPSR1EPHX1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008013427-A1 | ORGANIC TFTS AND METHOD FOR FABRICATING THE SAME | LG CHEM, LTD. (KR) | 2008-01-31 | — | — | WO | claimed |
| US-20240075151-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2024-03-07 | — | — | US | disclosed |
| US-11773219-B2 | Functionalized polymers | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-20230285574-A1 | CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2023-09-14 | — | — | US | disclosed |
| US-11723981-B2 | Conjugates of tumor necrosis factor inhibitors to functionalized polymers | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-08-15 | — | — | US | disclosed |
| US-20230022913-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2023-01-26 | — | — | US | disclosed |
| US-11382984-B2 | Conjugates of tumor necrosis factor inhibitors to functionalized polymers | QUIAPEG PHARMACEUTICALS AB (SE) | 2022-07-12 | — | — | US | disclosed |
| US-20220031856-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2022-02-03 | — | — | US | disclosed |
| US-20210283266-A1 | CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-09-16 | — | — | US | disclosed |
| US-20210206918-A1 | FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2021-07-08 | — | — | US | disclosed |
| US-20060084819-A1 | Total synthesis of myriaporones | LOSADA CARLOS D P | 2006-04-20 | — | — | US | disclosed |
| US-20060019960-A1 | Antitumoral analogs of ET-743 | PHARMA MAR, S.A. (ES) | 2006-01-26 | — | — | US | disclosed |
| EP-1287004-B1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF AN ECTEINASCIDIN COMPOUND | PHARMA MAR SA (ES) | 2005-07-27 | — | — | EP | disclosed |
| EP-1280809-B1 | ANTITUMORAL ECTEINASCIDIN DERIVATIVES | PHARMA MAR SA (ES) | 2005-07-06 | — | — | EP | disclosed |
| EP-1496060-A1 | Antitumoral analogs of ET-743 | PHARMA MAR, S.A. (ES) | 2005-01-12 | — | — | EP | disclosed |
| EP-1185536-B1 | HEMISYNTHETIC METHOD AND INTERMEDIATES THEREOF | PHARMA MAR SA (ES) | 2004-11-24 | — | — | EP | disclosed |
| EP-1289999-B1 | ANTITUMORAL ANALOGS OF ET-743 | PHARMA MAR SA (ES) | 2004-11-17 | — | — | EP | disclosed |
| US-5559249-A | 7'-amino-naphthazarin antibiotic derivatives | GRUPPO LEPETIT SPA (IT) | 1996-09-24 | — | — | US | disclosed |
| US-5530133-A | VAGINAL INFECTIONS | GRUPPO LEPETIT SPA (IT) | 1996-06-25 | — | — | US | disclosed |
| US-5475010-A | Vaginal infections | GRUPPO LEPETIT S.P.A. (IT) | 1995-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285574-A1 | CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS | CD44, EPCAM, ALG1 | NAAA 1656/4885RAD52 1814/4885NPSR1 1159/4885 |
| US-20230022913-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | TNF, TNFRSF1A, TNFSF11 | NAAA 2777/4885RAD52 2858/4885NPSR1 1910/4885 |
| US-20060084819-A1 | Total synthesis of myriaporones | CBR3, CBR1, SRR | NAAA 2995/4885RAD52 872/4885NPSR1 200/4885 |
| US-11723981-B2 | Conjugates of tumor necrosis factor inhibitors to functionalized polymers | TNF, TNFRSF1A, TNFSF11 | NAAA 2777/4885RAD52 2858/4885NPSR1 1910/4885 |
| US-11773219-B2 | Functionalized polymers | PARG, PUF60, PCBP1 | NAAA 2856/4885RAD52 760/4885NPSR1 1803/4885 |
| US-20210206918-A1 | FUNCTIONALIZED POLYMERS | PARG, PUF60, PCBP1 | NAAA 2856/4885RAD52 760/4885NPSR1 1803/4885 |
| US-20240075151-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | TNF, TNFRSF1A, TNFSF11 | NAAA 2777/4885RAD52 2858/4885NPSR1 1910/4885 |
| US-11382984-B2 | Conjugates of tumor necrosis factor inhibitors to functionalized polymers | TNF, TNFRSF1A, TNFSF11 | NAAA 2777/4885RAD52 2858/4885NPSR1 1910/4885 |
| US-20060019960-A1 | Antitumoral analogs of ET-743 | ETV1, ETV6, ETF1 | NAAA 4035/4885RAD52 1436/4885NPSR1 2881/4885 |
| US-20220031856-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | TNF, TNFRSF1A, TNFSF11 | NAAA 2777/4885RAD52 2858/4885NPSR1 1910/4885 |
| US-20210283266-A1 | CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS | CD44, EPCAM, ALG1 | NAAA 1656/4885RAD52 1814/4885NPSR1 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.